Center for the Study of Myelofibrosis, Research and Experimental Biotechnology Laboratory Area, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Policlinico San Matteo Foundation, Piazzale Golgi 19, 27100, Pavia, Italy.
Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Italy.
Crit Rev Oncol Hematol. 2018 Dec;132:89-99. doi: 10.1016/j.critrevonc.2018.09.005. Epub 2018 Sep 18.
Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth. RCC also frequently shows alterations in the mTOR signaling pathway, and mTOR inhibitors have shown a similar pattern of initial activity/late failure as pure antiangiogenic agents. Understanding mechanisms of resistance to these agents would be key to improve the outcome of our patients. Circulating endothelial cells are a family of mainly bone marrow-derived progenitors, which have been postulated to be responsible of the reactivation of angiogenesis in different tumors. In this review, we shall discuss the complex nature and function of these cells, the evidence pro and contra their contribution to tumor vascularization, especially as far as RCC is concerned, and their possible role in determining resistance to presently available treatments.
肾细胞癌 (RCC) 高度依赖血管生成,这是由于 VHL/HIF/VEGF/VEGFRs 轴的过度激活;这也解释了这种肿瘤对血管生成抑制剂的显著敏感性,但这些抑制剂最终无法控制肿瘤生长。RCC 还经常表现出 mTOR 信号通路的改变,而 mTOR 抑制剂的初始活性/后期失败模式与纯血管生成抑制剂相似。了解这些药物的耐药机制将是改善患者预后的关键。循环内皮细胞是一群主要来源于骨髓的祖细胞,它们被认为是不同肿瘤中血管生成重新激活的原因。在这篇综述中,我们将讨论这些细胞的复杂性质和功能,以及它们对肿瘤血管生成的贡献的正反两方面证据,特别是就 RCC 而言,以及它们在决定对现有治疗方法的耐药性方面的可能作用。